Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01123304 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma
A Phase 1 study, sponsored by Morphotek.
- Terminated
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT01123304: Clinical Trial Phase 1 study, sponsored by Morphotek.
NCT01123304 is a Phase 1 study that was terminated before completion, run by Morphotek. The registered enrollment target is 18 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01123304, a Phase 1 study, was terminated before completion, sponsored by Morphotek.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This research is being done to find out the safety of MORAb-028 in subjects with metastatic melanoma.
Primary Outcome
After each patient completes study treatment the patient is evaluated for dose limiting toxicities (DLTs) up to 1 week after their last dose (at day 33)
Interventions
- DRUG MORAb028
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2010-05 |
| Est. Completion | 2012-03 |
| Phase | Phase 1 |
Why NCT01123304 stopped before completion
NCT01123304 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower).
The record links to 0 conditions, and to 1 intervention - of which MORAb028 is the first listed.
NCT01123304 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01123304 about?
NCT01123304 is a clinical study titled "Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma". This research is being done to find out the safety of MORAb-028 in subjects with metastatic melanoma.
What is the current status of trial NCT01123304?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2010-05. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01123304?
The interventions under investigation include: MORAb028 (DRUG).
Who is sponsoring clinical trial NCT01123304?
This trial is sponsored by Morphotek, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01123304's enrollment target sits among peer trials
18 1720th of 2000 higher than 216 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia